Hostname: page-component-745bb68f8f-kw2vx Total loading time: 0 Render date: 2025-01-24T23:01:01.391Z Has data issue: false hasContentIssue false
  • English
  • Français

Phase II Study of Trimetrexate in Recurrent Anaplastic Glioma: National Cancer Institute of Canada Clinical Trials Group Study

Published online by Cambridge University Press:  18 September 2015

J. Gregory Cairncross ,
Elizabeth A. Eisenhauer ,
David R. Macdonald ,
Michel P. Rathbone ,
Malcolm J. Moore ,
Carol A. Sawka ,
Ronald E. MacCormick  and
Ian G. Kerr
J. Gregory Cairncross
Affiliation:
University of Western Ontario, London
Elizabeth A. Eisenhauer*
Affiliation:
National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston
David R. Macdonald
Affiliation:
University of Western Ontario, London
Michel P. Rathbone
Affiliation:
McMaster University, Hamilton
Malcolm J. Moore
Affiliation:
University of Toronto, Toronto
Carol A. Sawka
Affiliation:
University of Toronto, Toronto
Ronald E. MacCormick
Affiliation:
Dalhousie University, Halifax
Ian G. Kerr
Affiliation:
University of Toronto, Toronto
*
National Cancer Institute of Canada, Investigational New Drug Program, Queen's University, 82-84 Barrie St., Kingston, Ontario, Canada K7L 3N6
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The National Cancer Institute of Canada Clinical Trials Group conducted a phase II trial of trimetrexate given in a daily × 5 intravenous bolus schedule every 3 weeks in patients with measurable recurrent anaplastic glioma and limited prior treatment. There were no responses in 14 evaluable patients. We conclude that trimetrexate, given as described, is not an active agent in this disease.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 17 , Issue 1 , February 1990 , pp. 21 - 23
Copyright
Copyright © Canadian Neurological Sciences Federation 1990

References

REFERENCES

1.Young, B, Oldfield, EH, Markesbery, WR, et al. Re-operation for glioblastoma. J Neurosurg 1981; 55: 917–921.CrossRefGoogle ScholarPubMed
2.Gutin, PH, Leibel, SA, Wara, WM, et al. Recurrent malignant gliomas: survival following interstitial brachytherapy with highactivity iodine-125 sources. J Neurosurg 1987; 67: 864–871.CrossRefGoogle ScholarPubMed
3.Cairncross, JG, Macdonald, DR.Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988; 23: 360–364.CrossRefGoogle ScholarPubMed
4.Macdonald, DR, Cairncross, JG.Chemotherapy as initial treatment for aggressive oligodendroglioma. Neurology 1989; 39: 261.(Suppl1).Google Scholar
5.Edwards, MS, Levin, VA, Wilson, CB.Brain tumor chemotherapy: an evaluation of agents in current use in phase II and phase III trials. Cancer Treat Rep 1980; 64: 1179–1205.Google Scholar
6.Schold, SH, Cairncross, JG, Bullard, DE.Chemotherapy for primary brain tumors. In: Wilkins, RH, Rengachary, SS, eds. Neurosurgery New York: McGraw-Hill 1985; 1143–1153.Google Scholar
7.Kornblith, PL, Walker, MD.Chemotherapy for malignant gliomas. J Neurosurg New York: McGraw-Hill 1988; 68: 1–17.CrossRefGoogle ScholarPubMed
8.Richter, WE, Mccormack, JJ.Inhibition of mammalian dihydrofolate reductase by selected 2,4-diaminoquinazolines and related compounds. J Med Chem 1974; 17: 943–947.CrossRefGoogle Scholar
9.Clinical Brochure. Trimetrexate glucuronate (TMTX) NSC 352122. July 1984. Prepared by:Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland.Google Scholar
10.Ohnoshi, T, Ohnuma, T, Takahashi, I, et al.Establishment of methotrexate-resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists. Cancer Res 1982; 1655–1660.Google ScholarPubMed
11.Djerassi, I, Kim, JS, Reggev, A.Response of astrocytoma to high dose methotrexate with citrovorum rescue. Cancer 1985; 55: 2741–2747.3.0.CO;2-2>CrossRefGoogle Scholar
12.Eisenhauer, EA, Zee, BC, Pater, JL, et al. Trimetrexate: predictors of severe or life-threatening toxic effects. JNCI 1988; 80: 1318–1322.CrossRefGoogle ScholarPubMed